December 17, 2007 – Medtronic today announced it received Japanese regulatory approval on December 10, 2007 for the Sprint Quattro (Model 6944 and 6947) steroid-eluting right ventricular lead used with implantable cardioverter-defibrillators (ICDs) that detect and treat rapid heart rhythms, representing Japan’s first 8.6 French defibrillation lead to feature screw-in fixation.

FUJIFILM Medical Systems USA Inc. is the only DR vendor to offer facilities the choice of two similar but unique DR detectors, both of which provide the highest resolution and fastest image availability of any available DR system, according to the manufacturer.

December 14, 2007 - According to a guideline update published online today in the journals of the Society for Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC) and American Heart Association (AHA), patients treated with drug-eluting stents must take a combination of aspirin and the clot-reducing drug clopidogrel for at least one year, and possibly longer, after stent implantation.

December 14, 2007 - Boston Scientific Corp. has agreed to sell its Fluid Management and Venous Access businesses to Avista Capital Partners for $425 million in cash; the transaction is expected to close in the first quarter of 2008, subject to regulatory approvals and customary conditions

Avista said that upon close of the transaction, the combined Fluid Management/Venous Access business would operate as an independent company under a new name.

December 14, 2007 - Medtronic Inc. announced FDA clearance of Reveal DX and Reveal XT Insertable Cardiac Monitors (ICMs) designed to help physicians identify the cause of unexplained fainting or abnormal heart rhythms, including ventricular tachyarrhythmias (VT), fast ventricular tachyarrhythmias (FVT), bradyarrhythmias and asystole.

December 13, 2007 - The American Red Cross and the American Heart Association join in thanking Congress today for passing a bill designating the first week of June “National Cardiopulmonary Resuscitation (CPR) and Automated External Defibrillator (AED) Awareness Week.”

The organizations said the passage of this resolution shines a national spotlight on how important it is for all Americans to learn critical lifesaving skills such as how to perform CPR, how to use an AED and the need to increase public access to AEDs.

December 13, 2007 - Devax Inc. announced that it has completed patient enrollment in the DIVERGE clinical trial evaluating its novel AXXESS Bifurcation Stent System.

The prospective, multi-center trial that enrolled 302 patients, is the largest study conducted to date with a drug-eluting stent specifically designed for treating bifurcation lesions. Bifurcation lesions are areas of atherosclerotic disease occurring at a location where one large vessel divides into two smaller vessels.

December 13, 2007 – The Cardiovascular Research Foundation and colleagues, along with Gregg W. Stone, M.D., of Columbia University Medical Center, examined the one-year clinical outcomes of patients enrolled in ACUITY trial and found similar outcomes for ACS patients treated with different anticoagulant regimens.

December 13, 2007 - World Heart Corp., a developer of implantable mechanical circulatory support systems for chronic heart failure patients, announced its strategic alliance with Abiomed Inc., a leading manufacturer of devices for acute circulatory support.

FlowCardia's three peripheral CROSSER Catheters — CROSSER 14P, CROSSER 14S and CROSSER 18 CTO Recanalization — are endovascular tools used by interventional radiologists, vascular surgeons and interventional cardiologists to cross CTOs to help restore blood flow to the lower legs. The CROSSER is a rapid exchange catheter delivered over standard .014 inch and .018 inch guide wires that utilizes high frequency vibration to cross CTOs, reportedly allowing for subsequent debulking, balloon angioplasty and stent placement.

www.flowcardia.com

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now